I
t is well acknowledged that the buccal process of alveolar bone is entirely composed of bundle bone and is therefore more susceptible to undergo resorption after tooth extraction compared to the lingual/palatal process. [1] [2] [3] [4] [5] [6] [7] [8] Nevins et al. 9 reported that ‡20% of the buccal process of alveolar bone undergoes resorption within the first 12 weeks of tooth loss, whereas studies by Schropp et al. 7, 8 reported that nearly 66% of the alveolar bone undergoes resorption within the first 3 months of tooth extraction.
Results from a recent histologic study 4 on baboons emphasized that the buccal bone receives an essential share of its vascular supply from the adjacent interdental bone and not merely from the socket side of the alveolus. This study 4 also showed that extraction of multiple contiguous teeth is associated with a more intense alveolar bone remodeling around extraction sites because the interdental vascular supply is compromised to a much larger extent compared to when a single tooth is extracted. It has been reported that immediate implant placement in fresh extraction sites may prevent alveolar bone remodeling in the short term; 10, 11 however, localized osseous defects around immediate implants placed in fresh extraction sites may present a challenge to the clinician. 12 Guided bone regeneration (GBR) using barrier membranes has been applied in implant dentistry for increasing the width and height of the alveolar ridge in areas with insufficient bone. [9] [10] [11] [12] [13] Various combinations of resorbable membranes and bone grafts, such as collagen membranes (CMs) with demineralized freeze-dried bone allograft, CMs with deproteinized bovine bone, and dermal matrix membranes with bioactive glass have been used in GBR. 14, 15 Although studies 16, 17 have reported that placement of a barrier membrane over the bone grafts during GBR favors new bone formation around immediate implants, the contribution of resorbable membranes during GBR using xenografts and growth factors is unclear.
Growth factors are polypeptide hormones that regulate the cellular events associated with tissue regeneration and repair. [18] [19] [20] The platelet-derived growth factor (PDGF) has been comprehensively assessed with reference to periodontal regeneration. [19] [20] [21] [22] [23] [24] Studies [19] [20] [21] [22] [23] [24] have demonstrated that PDGF endorses formation of new bone tissues around immediate implants with periodontal bony defects in the presence, as well as absence, of barrier membranes. The present study is based on the null hypothesis that use of a resorbable barrier membrane during GBR with PDGF and xenograft does not enhance the buccal bone thickness (BBT), buccal bone volume (BBV), vertical bone height (VBH), and bone-to-implant contact (BIC) around immediate implants with buccal dehiscence-type defects.
The present microcomputed tomographic analysis aims to assess the efficacy of using PDGF and xenograft (either with or without a CM) on GBR around immediate implants with dehiscence-type defects in a canine model.
MATERIALS AND METHODS

Ethical Considerations
The study was approved by the ethical committee at the Engineer Abdullah Bugshan Research Chair for Growth Factors and Bone Regeneration (GFBR), King Saud University, Riyadh, Saudi Arabia. Preoperative animal care, all surgical procedures, and postoperative management of the animals were performed in accordance with the Animal Care Guidelines of GFBR.
Study Animals
Ten female beagle dogs with a mean age and weight of 19 -1 months and 13.8 -1.00 kg, respectively, were used. The animals were kept in individual cages and vaccinated against rabies and infectious hepatitis.
The non-surgical and surgical procedures were performed under general anesthesia § (10 mg/kg body weight).
Preoperative Management
During the housing period, the dogs underwent supragingival scaling twice a week for 3 weeks using an ultrasonic scaler. i Intramuscular amoxicillin ¶ (25 mg/kg body weight) was administered 1 day before surgery, followed by a second dose of the same antibiotic # at the time of surgery.
Animal Grouping and Treatment of Dehiscence Defects
The animals were randomly divided into three groups (by picking a paper marked ''group 1,'' ''group 2,'' or ''group 3'' from a brown bag). Animal grouping was based on the methodology adopted for the treatment of dehiscence defects: 1) group 1 (18 defects), in which xenograft** soaked in recombinant human (rh) PDGF-BB † † was placed over the defects and covered with a CM; ‡ ‡ 2) group 2 (18 defects), in which xenograft § § was soaked in rhPDGF-BB ii and placed over the defects; and 3) group 3 (four defects), in which four immediate implants ¶ ¶ were associated with dehiscence (controls, no treatment). In group 1 and group 2, 0.5 mL of 0.3 mg/mL rhPDGF was delivered using the particulate xenograft. ##22 
Surgical Protocol
After general anesthesia (as described above), animals were draped, and the surgical sites were swabbed with an antiseptic solution.*** Local anesthesia † † † was administered in the bilateral premolar regions of both arches. Teeth (second premolar [P2] and fourth premolar [P4]) were atraumatically extracted using piezosurgery. ‡ ‡ ‡ All buccal and lingual/palatal bone was sound with no dehiscence. Using a sulcular incision (with a no. 15 blade), full-thickness buccal and lingual/palatal flaps were raised to the mucogingival junction, after which a partial-thickness flap was raised to allow passive closure. Two vertical incisions (one mesial and one distal) were made. In each quadrant, P2 and P4 were extracted. A standardized hard acrylic stent § § § was used to create a dehiscence bony defect (3 · 6 mm) on the buccal surface of the extraction socket ( Fig.  1 ). This was followed by immediate implant iii (3.8 · 10.5 mm) placement in the distal extraction sockets (Fig. 1) and assignment of this site to one of the three groups. The surgical wounds were sutured ¶ ¶ ¶ to achieve primary closure.
Postoperative Management and Euthanasia
All animals received intramuscular (IM) injections of amoxicillin ### (25 mg/kg body weight) every 8 hours for 5 days. Analgesics**** (0.01 to 0.02 mg/kg, IM) were administered immediately after surgery and every 8 hours for the first 2 days after surgery and then whenever needed depending on the presence of signs of pain by the animal (such as restlessness, unusual calmness, or refusal to eat). Plaque control procedures, using topical application of a 0.2% chlorhexidine digluconate solution, † † † † were performed twice weekly for 4 months after surgery. Sutures ‡ ‡ ‡ ‡ were removed after 10 days of surgery, and the animals were kept on a soft diet throughout the study period.
After 4 months, the animals were sacrificed with an intravenous overdose of 3% sodium pentobarbital. § § § § Hard-Tissue Sectioning and Microcomputed Tomography The jaw segments containing the dental implants and associated mesial and distal tooth structures were removed en bloc using an electric saw iiii and fixed in 10% neutral formalin solution.
A microcomputed tomography (microCT) scanner ¶ ¶ ¶ ¶ was used to evaluate the BBT, BBV, VBH, and BIC around immediate implants. The x-ray generator of the microCT was operated at an accelerated potential of 101 kV with a beam current of 96 mA using an aluminum filter with a resolution of 37.41-mm pixels. The BBT was measured at every 1-mm level starting from the alveolar crest to the base of the defect (Figs. 2A and 2B). The BBV was measured as described in a recent study. 25 In the adjacent teeth, VBH was measured via linear measurements (in millimeters) that extended from the crest of the implant to the apical notch (Fig. 2C) . For BIC measurement, the total surface area of the region of interest (ROI) and the subset of the ROI surface that was intersected by binarized bone objects was measured via an analysis software. 3, 26 The parameter thus measured was called ''intersection surface'' that corresponded to BIC. The BIC was calculated (at ·100 magnification) as the percentage of implant surface in contact with the bone through the whole perimeter of the implant. 3, 26 Statistical Analyses Statistical analyses were performed using a statistical software. #### The power of the present study was 95% (common standard deviation of 1 mm and a = 0.05). One-way analysis of variance was used to determine the differences in means of the BBT, BBV, VBH, and BIC among the groups. P values 0.05 were considered to be statistically significant. The data were normally distributed.
RESULTS
BBT
The mean BBT was significantly higher around dehiscence defects in group 2 (1.533 -0.89 mm) compared to that in group 1 (0.745 -0.322 mm) (P <0.01) and group 3 (0.257 -0.232 mm) (P <0.05). There was no significant difference in the BBT between sites in group 1 (0.257 -0.232 mm) compared to group 3 (control group) (Figs. 3A, 4 , and 5).
BBV
The mean BBV was significantly higher around dehiscence defects in group 2 (67. (Figs. 3B, 4 , and 5).
VBH
The mean VBH was significantly higher around dehiscence defects in group 2 (6.36 -1.37 mm) compared to the control group (group 3) (0.00 -0.00 mm) (P <0.001). The mean VBH was significantly higher around dehiscence defects in group 1 (3.91 -2.68 mm) compared to the control group (group 3) (0.00 -0.00 mm) (P <0.05). VBH was significantly higher in group 1 (3.91 -2.68 mm) compared to group 3 (0.00 -0.00 mm) (P <0.05). There was no significant difference in the VBH between group 1 A) A graphic representation of the BBTaround immediate implants with dehiscence in sites in group 1 (purple circle: PDGF + xenograft + CM), group 2 (green circle: PDGF + xenograft), and group 3 (orange circle: control/no treatment). BBTwas significantly higher among sites in group 2 compared to sites in group 1 (P <0.01) and group 3 (P <0.05). *P <0.05; † P <0.01. B) A graphic representation of the BBV around immediate implants with dehiscence among sites in group 1 (purple circle: PDGF + xenograft + CM), group 2 (green circle: PDGF + xenograft) and group 3 (orange circle: control/no treatment). BBV was significantly higher among sites in group 2 compared to those in group 1 (P <0.05) and group 3 (P <0.001). *P <0.05; ‡ P <0.001. C) A graphic representation of the VBH around immediate implants with dehiscence among sites in group 1 (purple circle: PDGF + xenograft + CM), group 2 (green circle: PDGF + xenograft), and group 3 (orange circle: control/no treatment). VBH was significantly higher among sites in group 2 compared to those in group 1 (P <0.05) and group 3 (P <0.001). *P <0.05; ‡ P <0.001. D) A graphic representation of the BIC around immediate implants with dehiscence among sites in group 1 (purple circle: PDGF + xenograft + CM), group 2 (green circle: PDGF + xenograft), and group 3 (orange circle: control/no treatment). BIC was significantly higher among sites in group 2 compared to those in group 1 (P <0.05) and group 3 (P <0.01). *P <0.05; † P <0.01.
(3.91 -2.68 mm) and group 2 (6.36 -1.37 mm) (Figs. 3C and 4) .
BIC
The mean BIC was significantly higher around dehiscence defects in group 2 (67.25% -13.42%) compared to that in group 1 (36.25% -12.78%) (P <0.05) and group 3 (30.25% -7.27%) (P <0.01) (Figs. 3D and 4) . There was no significant difference in the mean BIC among sites in group 1 (36.25% -12.78%) and group 3 (30.25% -7.27%) (Figs. 3D, 4 , and 5).
There was no significant difference in the BBT, BBV, VBH, and BIC on the lingual surface of the implants among the three groups.
DISCUSSION
The present microcomputed tomographic results demonstrated that GBR around immediate implants with buccal dehiscence-type defects was enhanced when treated merely with xenograft and PDGF compared to when a CM was placed over the xenograft soaked in PDGF. These results are in accordance with studies [27] [28] [29] [30] [31] [32] that demonstrated that growth factors exhibit the potential to regenerate bone in dehiscence-type defects around implants. It has been hypothesized that the gel-like consistency of growth factors provides a spacemaking potential to the growth factor, and simultaneous use of graft material may hinder the collapse of the flap into the bone defect during the early healing phase. 32 Likewise, in a recent systematic review, 29 the authors reported that treatment of periodontal osseous defects with enamel matrix derivative (an amelogeninrich growth factor) is as effective as when resorbable membranes are used during GBR. Simion et al. 16, 18 hypothesized that barrier membranes obstruct the chemotactic effect of the growth factor on periosteal pluripotential mesenchymal cells. Similar results were reported by Kanou et al. 33 This may be an explanation for our results that demonstrated a higher BBT, BBV, and BIC around dehiscence treated with PDGF and xenograft alone compared to those covered with CM after placement of PDGF and xenograft over the defect. However, additional studies are warranted to investigate the influence of barrier membranes on the periosteal pluripotential mesenchymal cells.
Several studies [18] [19] [20] [21] [22] have shown that PDGF enhances periodontal regeneration by accelerating events, such as cellular chemoattraction, differentiation, and proliferation. Mott et al. 34 used fluorescence effects to investigate the effect of bone graft soaked in PDGF on osteoblastic proliferation around rat calvaria defects. The results demonstrated that use of bone grafts soaked in PDGF significantly enhanced osteoblastic proliferation in the defect sites compared to sites merely treated with bone graft. 34 In another study, Sanchez-Fernandez et al. 27 tested the A through C) A series of reconstructed axial microCT images illustrating the thickness of the newly formed buccal bone (green) around immediate implants with dehiscence defects in groups 1 through 3. D through F) A series of reconstructed sagittal microCT images illustrating the vertical height of the newly formed buccal bone around immediate implants with dehiscence defects in groups 1 through 3.
hypothesis that osteoclasts can regulate the chemotaxis of osteoblasts. The results demonstrated that mature osteoclasts produce factors including the PDGF that attract osteoblasts toward sites with osseous defects, thereby promoting new bone regeneration in the target tissues. 27 Similar results were reported by Park et al. 35 Likewise, Howes et al. 36 reported that PDGF enhances demineralized bone matrix-induced cartilage and bone formation. The present microCT results support these studies 27, 35, 36 because dehiscence defects treated merely with xenograft and PDGF displayed significantly more osseous regeneration compared to the defects treated with xenograft, PDGF, and CM. This reflects that the osteopromotive effects of PDGF are significant enough to induce new bone formation, and the contribution of a CM in this regard is redundant.
According to the present results, VBH and BIC were significantly higher around immediate implants where dehiscence sites were treated merely with xenograft and PDGF compared to sites covered with a CM after placement of PDGF and xenograft. A possible explanation in this regard may be extracted from a histologic study 37 in which the authors demonstrated that CMs have a short half-life and are susceptible to resorption. Early resorption of a CM may contribute to impeding the osteogenic activity taking place in the space beneath the membrane.
CONCLUSION
Within the limits of the present microCT experiment, it is concluded that GBR around immediate implants with dehiscence defects using PDGF and xenograft alone resulted in higher BBT, BBV, VBH, and BIC than when performed in combination with a CM.
Figure 5.
A series of reconstructed axial images (at four different sections of 1-mm intervals starting 1 mm below the cemento-enamel junction) illustrating the thickness of the newly formed buccal bone (green) among the three groups. In group 2 (PDGF + xenograft), bone regeneration around immediate implants with dehiscence defects was significantly higher in group 1 (PDGF + xenograft + CM) and group 3 (control/no treatment). Yellow arrows indicate the buccal surface.
